SHANGHAI & SAN FRANCISCO --Hansoh Pharma (3692:HK) a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for AI-accelerated drug discovery. Expansion of the partnership immediately follows completion of their first hit-discovery collaboration, which identified and experimentally confirmed several novel hit compounds for a previously challenging oncology target.
The collaboration began in November 2019 focused on identifying hit compounds that are specific towards an intractable drug target. Atomwise performed AI-based molecular screening using their proprietary AI technology, AtomNet, to generate compound hits with predicted activity against multiple mutant forms of the oncology targets for Hansoh. With AtomNet, the collaboration was able to screen an ultra-large and diverse virtual library of over 12 billion compounds, finding 200 predicted candidates displaying specificity for the targets in only 2 weeks from a single virtual screen.
For more information about the collaboration, please refer to
About Hansoh Pharma
Hansoh Pharma (3692:HK) is a leading biopharmaceutical company in China committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, together with its over 9,000 dedicated employees in China and United States.
Founded in 1995, Hansoh has fully integrated research and development, manufacturing, and commercial capabilities, supporting a leadership position in oncology, central nervous system (CNS), anti-infectives, gastrointestinal disorders, diabetes, and autoimmune diseases, among others. With 1,200 professionals across R&D, Hansoh has internally discovered and NMPA approved innovative products including morinidazole (迈灵达), a third-generation nitroimidazole antibiotic; PEG-loxenatide (孚来美),the first once-weekly long-acting GLP-1 analogue discovered and developed in China for the treatment of diabetes; flumatinib ( 昕 福 ), a second-generation BCR-ABL inhibitor for frontline treatment of chronic myeloid leukemia (CML); and almonertinib (阿美乐), a third-generation EGFR inhibitor for the treatment of NSCLC.
For more information, please visit www.hspharm.com.
About Atomwise
Atomwise Inc. invented the first deep learning AI technology for structure-based small molecule drug discovery. Created in 2012, today Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. Atomwise has raised over $50 million from leading venture capital firms to support the development and application of its AI technology. Learn more at atomwise.com or follow @AtomwiseInc.
